FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms over the nation’s drug supply.

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals. Under the agreement,